All articles by
Breakthrough Study Demonstrates that High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates
The CONVINCE Trial study compares high-dose hemodiafiltration with standard, high-flux hemodialysis. Study revealed a 23% decrease in mortality rates for patients treated with high-volume hemodiafiltration compared to those treated with more commonly used high-flux hemodialysis. Exploration of methods to increase adoption of hemodiafiltration (HDF) making this therapeutic option accessible to patients
AOP Health: Completed study strengthens clinical development program for ropeginterferon alpha 2b (BESREMi®) in polycythaemia vera
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell’Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer.
Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis
Results from ALPHA Phase III trial demonstrated statistically significant increase compared to placebo in mean hemoglobin from baseline to week 12. All key secondary endpoints met statistical superiority, showing danicopan reduced fatigue and anemia as well as the need for transfusions
Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions
Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.
Baxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs
Developed in collaboration with nurses and therapists to help ease the burden on critical care teams. Supports care teams as they address pulmonary, skin and mobility challenges common in the ICU environment. Launches in U.S. with global expansion planned to begin later this year
Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users
Medtronic plc(opens new window) (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system.
Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI
Abiomed, part of Johnson & Johnson MedTech[1], announces results of a third-party analysis showing that utilizing Impella during high-risk percutaneous coronary intervention (PCI) procedures may help physicians achieve a more complete revascularization compared to high-risk PCIs supported using an intra-aortic balloon pump (IABP). Previous studies have shown that a more complete revascularization can lead to longer survival[2],[3], a greater reduction in heart failure and angina symptoms[4], and an improved quality of life for the patient[5].
Ichnos Sciences gets FDA orphan drug designation for ISB 2001 trispecific antibody
This ODD comes as Ichnos, with approval from the HREC in Australia and FDA’s IND clearance, gears up to begin a Phase 1 first-in-human dose-escalation dose-expansion trial with ISB 2001 later this summer
IGC Pharma gets $12m line of credit from O-Bank for Alzheimer’s research
IGC Pharma’s research and development efforts are concentrated on the treatment of Alzheimer’s disease with three compounds at various stages of development including IGC-AD1
NS Pharma secures FDA rare paediatric disease designation for NS089/NCNP-02
NS089/NCNP-02 is an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy